ATHE vs. FDMT, ENGN, PBYI, KRRO, LFVN, SLS, FTLF, NKTX, CYBN, and TNGX
Should you be buying Alterity Therapeutics stock or one of its competitors? The main competitors of Alterity Therapeutics include 4D Molecular Therapeutics (FDMT), enGene (ENGN), Puma Biotechnology (PBYI), Korro Bio (KRRO), LifeVantage (LFVN), SELLAS Life Sciences Group (SLS), FitLife Brands (FTLF), Nkarta (NKTX), Cybin (CYBN), and Tango Therapeutics (TNGX). These companies are all part of the "pharmaceutical products" industry.
Alterity Therapeutics vs.
4D Molecular Therapeutics (NASDAQ:FDMT) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, community ranking, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.
Alterity Therapeutics has lower revenue, but higher earnings than 4D Molecular Therapeutics.
4D Molecular Therapeutics received 54 more outperform votes than Alterity Therapeutics when rated by MarketBeat users. Likewise, 65.56% of users gave 4D Molecular Therapeutics an outperform vote while only 62.50% of users gave Alterity Therapeutics an outperform vote.
Alterity Therapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.
In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Alterity Therapeutics. MarketBeat recorded 4 mentions for 4D Molecular Therapeutics and 1 mentions for Alterity Therapeutics. 4D Molecular Therapeutics' average media sentiment score of 0.78 beat Alterity Therapeutics' score of 0.00 indicating that 4D Molecular Therapeutics is being referred to more favorably in the media.
4D Molecular Therapeutics currently has a consensus target price of $29.56, indicating a potential upside of 746.86%. Alterity Therapeutics has a consensus target price of $12.00, indicating a potential upside of 182.35%. Given 4D Molecular Therapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe 4D Molecular Therapeutics is more favorable than Alterity Therapeutics.
4D Molecular Therapeutics has a beta of 2.87, meaning that its share price is 187% more volatile than the S&P 500. Comparatively, Alterity Therapeutics has a beta of 0.65, meaning that its share price is 35% less volatile than the S&P 500.
99.3% of 4D Molecular Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 9.6% of 4D Molecular Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Summary
4D Molecular Therapeutics beats Alterity Therapeutics on 10 of the 14 factors compared between the two stocks.
Get Alterity Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATHE and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Alterity Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:ATHE) was last updated on 5/24/2025 by MarketBeat.com Staff
